Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CE1226 in Emphysema Related to Alpha1 Antitrypsin Deficiency
NCT07326592Phase 4Recruiting
- Sponsor
- CSL Limited
- Start
- Sep 2026
- Primary completion
- Sep 2033
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of alpha-1-proteinase inhibitor in emphysema, alpha-1 antitrypsin deficiency (AATD), sponsored by CSL Limited. Started Sep 2026; status: recruiting.
02
Drugs
alpha-1-proteinase inhibitor
03
Conditions
emphysemaalpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NCT07326592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07326592.